09/06/21 -"Our target price hike is largely attributable to an increase in our peer-based valuations, as we have factored in a premium of 20% vs none earlier. We believe, given the recovery from the quality ..."
Pages
59
Language
English
Published on
09/06/21
You may also be interested by these reports :
03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...
29/05/26
Elekta’s Q4 results revealed an adjusted EBIT exceeding expectations, although sales fell short. The company offered qualitative guidance for ...
26/05/26
Piling up assets is no strategy
25/05/26
The modest TP reduction reflects downward revisions to DCF and NAV, driven by lower near-term earnings (as discussed in the ‘EPS’ section). While our ...